Pocket Program - CROI

Wednesday
March 6 Oral Sessions
Session 49 CROI 2013
C Wednesday, 2:30-4 pm; Hall B2
Poster Abstracts
(see full session listings starting on page 24)
Session 54. ART, Complications, and TB
Session 57. Accessory Proteins/Gag
Session 61. Macrophage HIV Interactions: Cell Biology and Treatment
Session 65. HIV Genotypes and Phenotypes
Session 68. HIV and Monocytes, Macrophages, and Dendritic Cells
Session 72. Microbial Translocation
Session 76. Neutralizing Antibodies and How to Stimulate Them
Session 81. Mechanism of HIV Latency and Reactivation
Session 83. Gene and Adoptive Immunotherapy
Session 91. NeuroAIDS Clinical Studies
Session 92. Neuroimaging Studies
Session 93. Human Genomics
Session 103. Compartment Penetration of ARV
Session 104. ARV Drug Interactions
Session 107. ART: Too Early or Too Late? Or Better Late than Never!
Session 108. ART: Host and Viral Determinants of Outcome
Session 109. ART: Care and Adherence
Session 125. Hepatitis C Virus Epidemiology and Clinical Outcomes
Session 129. HIV-associated Malignancies: Lymphoma
Session 136. Microbial Translocation Measurement and Associations
Session 139. ART Effects: Gene Expression and Cellular Function
Session 140. Frailty: From Mice to Men and Women
Session 142. Renal Disease: Diagnosis, Predictors, and Drugs
Session 145. TB: Incidence, Risk Factors, and Outcomes
Session 146. TB Diagnostics
Session 148. The “ART” of TB Treatment
Session 158. HIV Risk Factors, Prevalence, and Barriers to Care
Session 159. Family Planning: Unintended Pregnancy and Unmet Need
Session 160. HIV in Peri- and Post-menopause
Session 165. Pregnancy Complications among HIV + Women
Session 166. PMTCT: Maternal and Child Health Outcomes
Session 177. HIV and ART-related Complications and Treatment in
Children and Youth
Session 179. Tenofovir in Children
Session 181. Immune Response to Perinatal HIV
Session 182. Response to Pediatric Vaccines in Children and Youth
Session 185. Oral PrEP and ARV Adherence
Session 189. MSM in the Developing World
Session 192. Disease Progression, Morbidity, and Mortality
Session 195. Biological and Behavioral Transmission Risks
Session 196. Reducing Risk
Session 199. Virologic Failure, 2 nd - and 3 rd -line Therapy in RLS
22 20th Conference on Retroviruses and Opportunistic Infections
e Wednesday, 4-6 pm; B406
Session 50–Symposium
Progress in Deciphering HIV Protective Immunity,
a symposium in memory of Norman Letvin
Conveners:
Beatrice Hahn, Univ of Pennsylvania,
Philadelphia, US
Gary Nabel, Sanofi, Cambridge, MA, US
158
Viral Escape and Neutralizing Antibody
Evolution in Early HIV-1 Infection
Cynthia Derdeyn
Emory Univ, Atlanta, GA, US
159
The Promise and Challenge of Broad and
Potent Neutralizing Antibody Responses to
HIV-1
Mark Connors
HIV-Specific Immunity Section, NIAID, NIH, Bethesda, MD, US
160
The Role of CD4 T in Developing Durable
Antibody Responses and as HIV Vaccine
Hendrik Streeck
US Military HIV Res Prgm, Walter Reed Army Inst of Res, Henry
M Jackson Fndn, Silver Spring, MD
161
Stringent Control and Eventual Clearance of
Highly Pathogenic SIV by Effector Memory
T Cells
Louis Picker
Vaccine and Gene Therapy Inst, Oregon Natl Primate Res Ctr,
Oregon Hlth and Sci Univ, Beaverton, US
Objectives: This session is directed to clinicians and scientists
interested in basic immunology, the immunology of HIV infection,
or HIV vaccine development. It is assumed that participants will
have some knowledge of basic immunological concepts including
the impact of HIV on the immune system. At the completion of the
session, participants will be knowledgeable about how replicating
vaccine vectors might provide protection against SIV, how different
CD4 T cells populations may be active in fighting HIV infection,
how broadly neutralizing antibodies develop in some HIV + subjects,
and the characteristics and potential uses of newly discovered
broadly neutralizing antibodies.